icam5 32769 1 ap 199  (Proteintech)

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: A Pro-Endocrine Pancreatic Islet Transcriptional Program Established During Development Is Retained in Human Gallbladder Epithelial Cells

doi: 10.1016/j.jcmgh.2022.01.008

Figure Lengend Snippet: List of TaqMan Primer/Probe Gene Expression Assays for Real-Time qPCR on the TLDA Platform

Article Snippet: Hs00170285_m1 , ICAM5 , Intercellular adhesion molecule 5.

Techniques: Gene Expression, Binding Assay, Histone Deacetylase Assay, Marker

Journal: Psoriasis: Targets and Therapy

Article Title: TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses

doi: 10.2147/PTT.S535434

Figure Lengend Snippet: Single-cell transcriptomic analysis of TYK2, ICAM1, and ICAM5 expression in psoriasis epidermal cells. ( A ) Single-cell clustering identifies seven major cell types in the epidermis of psoriasis patients. ( B ) Subcluster analysis reveals 20 distinct cellular subtypes. ( C ) Expression distribution of TYK2, ICAM1, and ICAM5 across different cell types. ( D ) Enrichment of TYK2, ICAM1, and ICAM5 expression among cellular subtypes. ( E ) GO enrichment analysis of Type 5 cells, showing related molecular functions (MF), cellular components (CC), and biological processes (BP). ( F ) KEGG pathway analysis highlights the major signaling pathways enriched in Type 5 cells. ( G ) CellChat analysis reveals intercellular communication among DCs, monocytes, keratinocytes, and T cells in psoriatic epidermis. ( H ) ITGB-ICAM1 signaling network illustrates interactions between monocytes/macrophages and DCs or endothelial cells. ( I ) CellPhoneDB analysis uncovers ICAM1-mediated intercellular interaction networks.

Article Snippet: After antigen retrieval (eg, in sodium citrate buffer, pH 6.0, at 95–100 °C for 20 min) and blocking with immunohistochemical blocking solution (Beyotime, China) at 37 °C for 30 min, sections were incubated with primary antibodies against p-STAT3 (Y705) (GB150001-100, Servicebio, Wuhan, China), ICAM1 (GB11106-100, Servicebio, Wuhan, China), or ICAM5 (12,759-1-AP, Proteintech, Wuhan, China) at 37 °C for 45 min. After washing with PBS, sections were incubated with fluorophore-conjugated secondary antibodies (eg, Alexa Fluor 488- or 594-conjugated goat anti-rabbit IgG, Thermo Fisher Scientific, 1:500 dilution) at 37 °C for 45 min.

Techniques: Expressing, Protein-Protein interactions

Journal: Psoriasis: Targets and Therapy

Article Title: TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses

doi: 10.2147/PTT.S535434

Figure Lengend Snippet: Effect of TYK2 P1104A mutation on LPS-induced inflammation and ICAM1 expression. ( A ) qPCR analysis of the impact of TYK2 P1104A mutation on LPS-induced mRNA expression of ICAM1 and ICAM5 (n = 5). ( B ) ELISA quantification of IL-1β, TNF-α, and IL-23 secretion before and after LPS treatment (n = 5). ( C ) qPCR analysis of LPS-induced mRNA expression of pro-inflammatory cytokines including IL-1β, TNF-α, IL-23, IL-6, and IL-18 (n = 5). ( D ) Immunofluorescence staining to assess the effects of TYK2 P1104A mutation on protein expression of ICAM1 and ICAM5 (magnification, 200×; scale bar, 50 µm). Significant differences were denoted by ns (not significant) (n = 5), * (P < 0.05), ** (P < 0.01), *** (P < 0.001) and **** (P < 0.0001).

Article Snippet: After antigen retrieval (eg, in sodium citrate buffer, pH 6.0, at 95–100 °C for 20 min) and blocking with immunohistochemical blocking solution (Beyotime, China) at 37 °C for 30 min, sections were incubated with primary antibodies against p-STAT3 (Y705) (GB150001-100, Servicebio, Wuhan, China), ICAM1 (GB11106-100, Servicebio, Wuhan, China), or ICAM5 (12,759-1-AP, Proteintech, Wuhan, China) at 37 °C for 45 min. After washing with PBS, sections were incubated with fluorophore-conjugated secondary antibodies (eg, Alexa Fluor 488- or 594-conjugated goat anti-rabbit IgG, Thermo Fisher Scientific, 1:500 dilution) at 37 °C for 45 min.

Techniques: Mutagenesis, Expressing, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Staining

Journal: Psoriasis: Targets and Therapy

Article Title: TYK2 rs34536443 (P1104A) Variant Suppresses ICAM1-Mediated Inflammation: Insights From Mendelian Randomization and Functional Analyses

doi: 10.2147/PTT.S535434

Figure Lengend Snippet: Effect of TYK2-P1104A mutation and Deucravacitinib on STAT3 phosphorylation and ICAM1/ICAM5 expression. ( A ) Immunofluorescence analysis of the effect of TYK2-P1104A mutation on LPS-induced phosphorylation of STAT3 (p-STAT3) (magnification, 200×; scale bar, 50 µm) (n = 5). ( B ) Expression levels of ICAM1 and ICAM5 in lesional skin tissues from IMQ-induced psoriasis-like mouse models following Deucravacitinib treatment. Significant differences were denoted by ns (not significant), ** (P < 0.01), *** (P < 0.001) and **** (P < 0.0001).

Article Snippet: After antigen retrieval (eg, in sodium citrate buffer, pH 6.0, at 95–100 °C for 20 min) and blocking with immunohistochemical blocking solution (Beyotime, China) at 37 °C for 30 min, sections were incubated with primary antibodies against p-STAT3 (Y705) (GB150001-100, Servicebio, Wuhan, China), ICAM1 (GB11106-100, Servicebio, Wuhan, China), or ICAM5 (12,759-1-AP, Proteintech, Wuhan, China) at 37 °C for 45 min. After washing with PBS, sections were incubated with fluorophore-conjugated secondary antibodies (eg, Alexa Fluor 488- or 594-conjugated goat anti-rabbit IgG, Thermo Fisher Scientific, 1:500 dilution) at 37 °C for 45 min.

Techniques: Mutagenesis, Phospho-proteomics, Expressing, Immunofluorescence

Journal: Journal of Inflammation Research

Article Title: Involvement of ICAM5 in Carcinostasis Effects on LUAD Based on the ROS1-Related Prognostic Model

doi: 10.2147/JIR.S475088

Figure Lengend Snippet: ( A ) Expression of ICAM5 in normal and tumor tissues of pan-cancer cohorts. ( B ) IHC staining images of ICAM5 in normal lung tissue and LUAD. ( C ) Differences in HLA genes expression in LUAD cohort. ( D ) Differences in immunostimulatory factors expression in LUAD cohort. ( E ) Differences in the results of the ESTIMATE algorithm in pan-cancer cohort. ( F ) Forest plot demonstrating the effect of ICAM5 expression in LUAD on OS, DSS, PFI and DFI. ( G ) KM survival analysis of OS in LUAD. ( H, I ) Enrichment plots from GSEA in the high- ICAM5 expression group and low- ICAM5 expression group. *0.01< p <0.05; **0.001< p <0.01; ***0.0001< p <0.001; **** p <0.0001; ns, not significant.

Article Snippet: Immunohistochemistry (IHC) staining images of ICAM5 from LUAD and healthy lung tissue were obtained from the Human Protein Atlas database ( https://www.proteinatlas.org/ ).

Techniques: Expressing, Immunohistochemistry